<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38366966</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1437-4331</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>27</Day></PubDate></JournalIssue><Title>Clinical chemistry and laboratory medicine</Title><ISOAbbreviation>Clin Chem Lab Med</ISOAbbreviation></Journal><ArticleTitle>Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms: a systematic review of the literature.</ArticleTitle><Pagination><StartPage>1044</StartPage><EndPage>1052</EndPage><MedlinePgn>1044-1052</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/cclm-2024-0036</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Viral persistence is one of the main hypotheses explaining the presence of post-COVID symptoms. This systematic review investigated the presence of SARS-CoV-2 RNA in plasma, stool, urine, and nasal/oral swab samples in individuals with post-COVID symptomatology.</AbstractText><AbstractText Label="CONTENT" NlmCategory="BACKGROUND">MEDLINE, CINAHL, PubMed, EMBASE, Web of Science databases, as well as medRxiv/bioRxiv preprint servers were searched up to November 25th, 2023. Articles investigating the persistence of SARS-CoV-2 RNA in plasma, stool, urine or nasal/oral swab samples in patients with post-COVID symptoms were included. Methodological quality was assessed using the Newcastle-Ottawa Scale or Cochrane's Risk of Bias (Rob) tool.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">From 322 studies identified, six studies met all inclusion criteria. The sample included 678 COVID-19 survivors (52&#x202f;% female, aged from 29 to 66 years). The methodological quality was moderate in 88&#x202f;% of the studies (n=5/6). Three papers investigated the presence of SARS-CoV-2 RNA in plasma, three studies in nasal/oral swabs, two studies in stool samples, one in urine and one in saliva. The follow-up was shorter than two months (&lt;60 days after) in 66&#x202f;% of the studies (n=4/6). The prevalence of SARS-CoV-2 RNA ranged from 5 to 59&#x202f;% in patients with post-COVID symptoms the first two months after infection, depending on the sample tested, however, SARS-CoV-2 RNA was also identified in COVID-19 survivors without post-COVID symptoms (one study).</AbstractText><AbstractText Label="OUTLOOK" NlmCategory="CONCLUSIONS">Available evidence can suggest the presence of persistent SARS-CoV-2 RNA in post-COVID patients in the short term, although the biases within the studies do not permit us to make firm assumptions. The association between post-COVID symptoms and SARS-CoV-2 RNA in the samples tested is also conflicting. The lack of comparative group without post-COVID symptoms limits the generalizability of viral persistence in post-COVID-19 condition.</AbstractText><CopyrightInformation>&#xa9; 2024 Walter de Gruyter GmbH, Berlin/Boston.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, 619352 Universidad Rey Juan Carlos (URJC) , Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres-Macho</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre 571738 , Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, 571738 Universidad Complutense de Madrid , Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macasaet</LastName><ForeName>Raymart</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, 24054 Monmouth Medical Center , Long Branch, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velasco</LastName><ForeName>Jacqueline Veronica</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Surgery, 125865 University of Santo Tomas , Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ver</LastName><ForeName>Abbygail Therese</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Surgery, 125865 University of Santo Tomas , Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culasino Carandang</LastName><ForeName>Timothy Hudson David</ForeName><Initials>THD</Initials><AffiliationInfo><Affiliation>Planetary and Global Health Program, St. Luke's Medical Center College of Medicine, Quezon City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerrero</LastName><ForeName>Jonathan Jaime</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>College of Medicine, 54725 University of the Philippines Manila , Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco-Moreno</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre 571738 , Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, 1500 Johns Hopkins University School of Medicine , Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Notarte</LastName><ForeName>Kin Israel</ForeName><Initials>KI</Initials><Identifier Source="ORCID">0000-0002-6055-0886</Identifier><AffiliationInfo><Affiliation>Department of Pathology, 1500 Johns Hopkins University School of Medicine , Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Chem Lab Med</MedlineTA><NlmUniqueID>9806306</NlmUniqueID><ISSNLinking>1434-6621</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="Y">RNA, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword><Keyword MajorTopicYN="N">review</Keyword><Keyword MajorTopicYN="N">viral persistence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>29</Day><Hour>13</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>17</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>17</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38366966</ArticleId><ArticleId IdType="doi">10.1515/cclm-2024-0036</ArticleId><ArticleId IdType="pii">cclm-2024-0036</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO coronavirus (COVID-19) dashboard 2023 . https://covid19.who.int/ [Accessed 8 Feb 2024].</Citation></Reference><Reference><Citation>Hospitalized adults: therapeutic management | COVID-19 treatment guidelines. COVID-19 treatment guidelines . https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/hospitalized-adults--therapeutic-management/ [Accessed 14 Sep 2023].</Citation></Reference><Reference><Citation>Nonhospitalized adults: therapeutic management | COVID-19 treatment guidelines. COVID-19 treatment guidelines . https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/ [Accessed 14 Sep 2023].</Citation></Reference><Reference><Citation>Zheng, C, Shao, W, Chen, X, Zhang, B, Wang, G, Zhang, W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis 2022;114:252&#x2013;60. https://doi.org/10.1016/j.ijid.2021.11.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, K, Wang, L, Li, M, Xie, B, He, L, Wang, M, et al.. Real-word effectiveness of global COVID-19 vaccines against SARS-CoV-2 variants: a systematic review and meta-analysis. Front Med 2022;9:820544. https://doi.org/10.3389/fmed.2022.820544 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.820544</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as, C. Long COVID: current definition. Infection 2022;50:285&#x2013;6. https://doi.org/10.1007/s15010-021-01696-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01696-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano, JB, Murthy, S, Marshall, JC, Relan, P, Diaz, JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102&#x2013;7. https://doi.org/10.1016/S1473-3099(21)00703-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes, LD, Ingram, J, Sculthorpe, NF. More than 100 persistent symptoms of SARS-CoV-2 (long COVID): a scoping review. Front Med 2021;8:750378. https://doi.org/10.3389/fmed.2021.750378 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.750378</ArticleId></ArticleIdList></Reference><Reference><Citation>Amdal, CD, Pe, M, Falk, RS, Piccinin, C, Bottomley, A, Arraras, JI, et al.. Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review. Qual Life Res 2021;30:3367&#x2013;81. https://doi.org/10.1007/s11136-021-02908-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-021-02908-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Tene, L, Bergroth, T, Eisenberg, A, David, SSB, Chodick, G. Risk factors, health outcomes, healthcare services utilization, and direct medical costs of patients with long COVID. Int J Infect Dis 2023;128:3&#x2013;10. https://doi.org/10.1016/j.ijid.2022.12.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.12.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as, C, Palacios-Ce&#xf1;a, D, G&#xf3;mez-Mayordomo, V, Florencio, LL, Cuadrado, ML, Plaza-Manzano, G, et al.. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur J Intern Med 2021;92:55&#x2013;70. https://doi.org/10.1016/j.ejim.2021.06.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2021.06.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, C, Haupert, SR, Zimmermann, L, Shi, X, Fritsche, LG, Mukherjee, B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022;226:1593&#x2013;607. https://doi.org/10.1093/infdis/jiac136 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi, MS, Omrani, OA, Fawzy, NA, Shaar, BA, Almamlouk, R, Riaz, M, et al.. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect 2022;28:657&#x2013;66. https://doi.org/10.1016/j.cmi.2022.01.014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, Q, Zheng, B, Daines, L, Sheikh, A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens 2022;11:269. https://doi.org/10.3390/pathogens11020269 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-las-Pe&#xf1;as, C, Notarte, KI, Macasaet, R, Velasco, JV, Catahay, JA, Ver, AT, et al.. Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: a systematic review and meta-analysis. J Infect 2024;88:77&#x2013;88. https://doi.org/10.1016/j.jinf.2023.12.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.12.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran, AV. Long COVID-19: challenges in the diagnosis and proposed diagnostic criteria. Diabetes Metab Syndr 2021;15:145&#x2013;6. https://doi.org/10.1016/j.dsx.2020.12.025 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.12.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero, D, Chalon, P, Kohn, L, Dauvrin, M, Detollenaere, J, Maertens de Noordhout, C, et al.. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med 2022;54:1473&#x2013;87. https://doi.org/10.1080/07853890.2022.2076901 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2076901</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif, ZA, Gomez, CR, Connors, TJ, Henrich, TJ, Reeves, WB. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife 2023;12:e86002. https://doi.org/10.7554/eLife.86002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86002</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell, JS, Chappell, KJ. Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)? Front Microbiol 2021;12:724654. https://doi.org/10.3389/fmicb.2021.724654 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.724654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, B, Julg, B, Mohandas, S, Bradfute, SB. Viral persistence, reactivation, and mechanisms of long COVID. Elife 2023;12:e86015. https://doi.org/10.7554/eLife.86015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86015</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal, AD, VanElzakker, MB, Aleman, S, Bach, K, Boribong, BP, Buggert, M, et al.. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol 2023;24:1616&#x2013;27. https://doi.org/10.1038/s41590-023-01601-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Bussani, R, Zentilin, L, Correa, R, Colliva, A, Silvestri, F, Zacchigna, S, et al.. Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19. J Pathol 2023;259:254&#x2013;63. https://doi.org/10.1002/path.6035 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.6035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner, A, Koch, R, Jukic, A, Pfister, A, Meyer, M, R&#xf6;ssler, A, et al.. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology 2022;163:495&#x2013;506. https://doi.org/10.1053/j.gastro.2022.04.037 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https://doi.org/10.1136/bmj.n71 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells, G, Tugwell, P, O&#x2019;Connell, D, Welch, V, Peterson, J, Shea, B, et al.. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2015.</Citation></Reference><Reference><Citation>Stein, SR, Ramelli, SC, Grazioli, A, Chung, J-Y, Singh, M, Yinda, CK, et al.. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 2022;612:758&#x2013;63. https://doi.org/10.1038/s41586-022-05542-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank, Z, Senussi, Y, Manickas-Hill, Z, Yu, XG, Li, JZ, Alter, G, et al.. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis 2023;76:e487&#x2013;90. https://doi.org/10.1093/cid/ciac722 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweitzer, F, Goereci, Y, Franke, C, Silling, S, B&#xf6;sl, F, Maier, F, et al.. Cerebrospinal fluid analysis post-COVID-19 is not suggestive of persistent central nervous system infection. Ann Neurol 2022;91:150&#x2013;7. https://doi.org/10.1002/ana.26262 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina, F, Catalan, P, Rodriguez-Grande, C, Adan, J, Rodriguez-Gonzalez, C, Mu&#xf1;oz, P, et al.. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect Dis 2022;22:211. https://doi.org/10.1186/s12879-022-07153-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, X, Lu, S, Li, H, Wang, Y, Lu, Z, Liu, Z, et al.. Viral and antibody kinetics of COVID-19 patients with different disease severities in acute and convalescent phases: a 6-month follow-up study. Virol Sin 2020;35:820&#x2013;9. https://doi.org/10.1007/s12250-020-00329-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00329-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan, A, Zlitni, S, Brooks, EF, Vance, SE, Dahlen, A, Hedlin, H, et al.. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med 2022;3:371&#x2013;87. https://doi.org/10.1016/j.medj.2022.04.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso, MJ, Deitchman, AN, Torres, L, Iyer, NS, Munter, SE, Nixon, CC, et al.. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 2021;36:109518. https://doi.org/10.1016/j.celrep.2021.109518 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, Y, Yuan, D, Chen, DG, Ng, RH, Wang, K, Choi, J, et al.. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022;185:881&#x2013;95.e20. https://doi.org/10.1016/j.cell.2022.01.014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock, V, Mahajan, A, Spikes, L, Krishnamachary, B, Ram, AK, Kumar, A, et al.. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol 2023:95:e28568. https://doi.org/10.1002/jmv.28568 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi, P, Gorelik, Y, Gausi, B, Bernstine, T, Edelstein, M. Characterization of post-COVID syndromes by symptom cluster and time period up to 12 months post-infection: a systematic review and meta-analysis. Int J Infect Dis 2023;134:1&#x2013;7. https://doi.org/10.1016/j.ijid.2023.05.003 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney, LL, Routen, A, Gillies, C, Ekezie, W, Welford, A, Zhang, A, et al.. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine 2023;55:101762. https://doi.org/10.1016/j.eclinm.2022.101762 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian, V, Elghazaly, H, Chattopadhyay, R, Debski, M, Naing, TKP, Garg, P, et al.. Risk factors associated with post-COVID-19 condition. JAMA Intern Med 2023;183:566&#x2013;80. https://doi.org/10.1001/jamainternmed.2023.0750 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, D, Mei, B, Wang, P, Li, X, Chen, X, Wei, G, et al.. Prevalence and risk factors for persistent symptoms after COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect 2023. https://doi.org/10.1016/j.cmi.2023.10.016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.10.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso, D, Martino, L, Morello, R, Mariani, F, Fearnley, K, Valentini, P. Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies. Lancet Microbe 2023;4:e745&#x2013;56. https://doi.org/10.1016/s2666-5247(23)00115-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-5247(23)00115-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as, C, Torres-Macho, J, Catahay, JA, Macasaet, R, Velasco, JV, Macapagal, S, et al.. Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review. Infection 2024;52:43&#x2013;58. https://doi.org/10.1007/s15010-023-02154-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02154-0</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>